The QualityStocks Daily Tuesday, February 4th, 2020

Today's Top 3 Investment Newsletters

MarketClub Analysis (MYO) +114.71%

StockMarketWatch (IBIO) +61.69%

QualityStocks (AGHC) +58.38%

The QualityStocks Daily Stock List

Ascent Solar Technologies, Inc. (ASTI)

Zacks, Microcap Daily, Stocktwits, CSIMarket, Stock of the Week, Infront Analytics, Investing.com, The Wolf Of Penny Stocks, Ready Ratios, OTC.Watch, Morningstar, InvestorsHub, Economies.com, Equities.com, Nasdaq, Insider Financial, Dividend Investor, Proactive Investors, Stockwatch, Simply Wall St, Seeking Alpha, GuruFocus, Stockhouse, Green Leaf Pot Stocks, TradingView, Wallet Investor, and YCharts reported beforehand on Ascent Solar Technologies, Inc. (ASTI), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Ascent Solar Technologies, Inc. is a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) solutions. It designs, manufactures, and sells PV integrated consumer electronics and portable power applications for commercial and military users. The Company markets and sells its products via distributors, value added resellers, as well as e-commerce companies.

Established in 2005, Ascent Solar Technologies is based in Thornton, Colorado, where its Research and Development (R&D) and its 30 MW nameplate production facility are. Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine. In addition, they were named one of TIME Magazine's 50 best inventions for 2011.

The Company is a developer of thin-film PV modules using flexible substrate materials that are more versatile and sturdy than traditional solar panels. The technology represents the leading edge of flexible power. It can be directly integrated into consumer products and off-grid applications, and also other aerospace applications. Ascent Solar Technologies provides solar solutions from bare modules to finished goods and everything in between.

The Company has its patented 3-step manufacturing process. Step 1 is thin-film deposition. Step 2 is monolithic integration. Step 3 is final assembly. Ascent’s inventive monolithic integration process enables the highest level of efficiency, durability and weight savings. This represents the potential to transform the way solar power can be used in everyday life. The Company’s solar technology and power solutions are for remote locations and extreme environments. Regarding its IP (Intellectual Property), Ascent Solar Technologies has more than 80 U.S. and International issued patents and published patent applications.

Ascent develops and manufactures its innovative CIGS (Copper-Indium-Gallium-Selenide) photovoltaic technology on a flexible, plastic substrate. The design of these panels are to convert sunlight into electric power through laying a thin layer of these four elements onto a plastic backing.

The Company is a leader in the CIGS field. It is the only manufacturer commercially producing CIGS solar on a plastic substrate with monolithic integration, which is an important differentiator for the Company.

Ascent Solar Technologies, Inc. (ASTI), closed Monday's trading session at $2.28, even for the day, on 50 volume with 1 trade. The average volume for the last 3 months is 1,314 and the stock's 52-week low/high is $1.15999996/$2.99.

chart

Bluestone Resources, Inc. (BBSRF)

Mining News Feed, Street Insider, Street Signals, Financial Buzz, Gold Newsletter, Junior Mining Network, Geology for Investors, InvestorX, Northern Miner, Micro Small Cap, Market Wire News, Metals News, MarketWatch, Morningstar, Simply Wall St, TradingView, Nasdaq, Think Geoenergy, Stockhouse, Wallet Investor, Wallmine, Canadian Mining Journal, GuruFocus, 4-Traders, and The Prospector News reported beforehand on Bluestone Resources, Inc. (BBSRF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Bluestone Resources, Inc. is a mineral exploration and development company headquartered in Vancouver, British Columbia. It is advancing its 100 percent-owned Cerro Blanco Gold and Mita Geothermal projects in Guatemala. Bluestone was established in 2017 with the purchase of these projects. The Company formerly went by the name Indicator Minerals, Inc. It changed its corporate name to Bluestone Resources, Inc. in January of 2012. Bluestone Resources’ shares trade on the OTC Markets Group’s OTCQB.

The Cerro Blanco Gold Project is a permitted, high-grade underground gold project located in southeastern Guatemala. A Feasibility Study (FS) on Cerro Blanco returned strong economics with a speedy pay back. The average annual production is projected to be 146,000 ounces per year over the first three years of production with all-in sustaining costs (AISC) of $579/oz. The Cerro Blanco Gold Project has an 8 years (initial) estimated mine life. The Resource Grade is M&I Grade 10.1 G/T Gold.

The Mita Geothermal project is an advanced-stage, renewable energy project. It is licensed to produce up to 50 megawatts of power. The Mita Geothermal project is in southeast Guatemala roughly 160 kilometers by road from the capital, Guatemala City. A total of 19 geothermal wells have been drilled. This includes nine slim holes and ten standard diameter wells. In 2013, an FS was completed on the Mita Geothermal project by Sinclair Knight Merz (SKM) which returned positive economics.

Last week, Bluestone Resources announced that it entered into a US$30 million credit facility with Natixis. Natixis is a French multinational financial services firm. It is one of the lending banks in connection with a potential senior debt project financing package. The proceeds from the Credit Facility will be used for detailed design and engineering, early development work at the Cerro Blanco gold project, and also for general corporate purposes.

Additionally, Bluestone Resources announced last week the appointment of Mr. Jack Lundin to the Management Team and Board of Directors. Mr. Lundin will assume the Chief Executive Officer (CEO) role, with current President & CEO, Mr. Darren Klinck retaining the role of President.

Mr. Lundin has experience in mine project development. He has just come off the successful execution of Lundin Gold's Fruta del Norte (FDN) Gold Mine in Southern Ecuador where he served as the Project Superintendent. He brings with him a recognized legacy and years of natural resource technical and economic expertise.

Bluestone Resources, Inc. (BBSRF), closed Monday's trading session at $0.1416, off by 6.312%, on 5,500 volume with 4 trades. The average volume for the last 3 months is 2,876 and the stock's 52-week low/high is $0.1268/$0.370000004.

chart

CarSmartt, Inc. (CRSM)

InvestorBrandNetwork, FortuneNewsWire, StockPulse, Trader Newswire, TipRanks, Street Insider, OTC Markets, OTC Dynamics, Seeking Alpha, Simply Wall St, Morningstar, GuruFocus, last10k, PR Newswire, Dividend Investor, Wallmine, Investors Hangout, Stockopedia, Nasdaq, Wallet Investor, TradingView, Stockhouse, InvestorsHub, Global Banking and Finance Review, GlobeNewswire, and Dividend Investor reported earlier on CarSmartt, Inc. (CRSM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

CarSmartt, Inc. is an American transportation network company (TNC) offering a peer-to-peer ridesharing service. Its platform can be accessed through its mobile app (Android and iOS). The Company formerly went by the name Sports Supplement Group, Inc. It changed its corporate name to CarSmartt®, Inc. in February of 2018. The Company serves markets in the Southeast region of the United States. CarSmartt has its head office in Coral Gables, Florida. The Company lists on the OTC Markets.

All CarSmartt drivers are subject to background checks to reassure the safety of the Company’s passengers. CarSmartt’s application is made to connect drivers with the world's travelers to make long-distance trips affordable. CarSmartt provides ridesharing services to users via their App at app.carsmartt.com.

CarSmartt’s mission is to democratize mobility and create a liberated ecosystem for road transportation. This means being more economic for drivers, and also efficient, transparent, eco-friendly, and higher earnings for drivers.

CarSmartt announced in May of 2019 the completion of the new Carsmartt App (iOS and Android). The platform has many features that enable CarSmartt's drivers to earn more money and allow riders to save more on fares.

Every driver who wants to work with CarSmartt needs to log in to the GoodHire site and submit their information by way of a link that will be posted on the Company’s website. This ensures third party verification of CarSmartt drivers and increases the level of security considerably.

Last week, CarSmartt announced its user growth and its start of development on its new "YouSmartt" service. YouSmartt will provide, for all CarSmartt participants, access to a proprietary network of up to 45 discounted ancillary offerings. This will include, but is not limited to, the areas of Beauty, Home Care, Auto Care, Pet Care, Child Care, Personal Care, Education, Technology Services, Entertainment, Travel, and Leisure.

CarSmartt, Inc. (CRSM), closed Monday's trading session at $0.2935, off by 13.6765%, on 655,918 volume with 222 trades. The average volume for the last 3 months is 505,386 and the stock's 52-week low/high is $0.0041/$0.485100001.

chart

Edesa Biotech, Inc. (EDSA)

Whale Wisdom, Stocktwits, MicroSmallCap, Market Chameleon, Investor Place, Street Insider, Proactive Investors, TipRanks, ChartMill, Accesswire, GuruFocus, Simply Wall St, YCharts, Investors Observer, InvestorsHub, PR Newswire, MusthInsider, Stockwatch, iwatchmarkets, TradingView, Morningstar, Barchart, Stockopedia, and Seeking Alpha reported earlier on Edesa Biotech, Inc. (EDSA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company based in Markham, Ontario. Its emphasis is on efficiently developing unique treatments that address significant unmet medical needs. The Company’s lead product candidate is EB01. Late-stage drug candidates developed by Edesa Biotech aim to help patients with limited treatment options for dermatological and gastrointestinal diseases. Edesa also has U.S. offices in Southern California in Port Hueneme. Founded in 2015, Edesa Biotech lists on the NasdaqCM. Experts in the field of dermatology and gastroenterology founded the Company.

Edesa’s EB01 is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis that has demonstrated statistically significant improvements in numerous clinical studies. In October of 2019, a Phase 2b clinical study of EB01 was started. The design of sPLA2 inhibitors are to inhibit the inflammatory process at its inception rather than after inflammation has occurred. In addition, Edesa Biotech’s intention is to expand the utility of its sPLA2 inhibitor technology across manifold indications and also expand its portfolio with assets that can propel long-term growth opportunities.

Edesa intends to expand its pipeline across multiple indications. This could include acne or other inflammatory disorders. For instance, EB02 is a formulation developed to treat hemorrhoids. In addition, Edesa has licensed other technology. Moreover, the Company is in discussions to broaden its portfolio with investigational medicines to treat other serious skin and gastrointestinal conditions.

Edesa Biotech’s Clinical Pipeline status as of December 1, 2019 includes EB01 - Contact Dermatitis – Topical, and EB02 – Hemorrhoids – Topical. Its Clinical Pipeline also includes EB04 – Anal - Fissures – Topical.

This past December, Edesa Biotech reported that its lead product candidate, EB01, demonstrated positive safety data in healthy volunteers participating in its continuing Phase 2b clinical study in chronic allergic contact dermatitis (ACD). The healthy volunteer cohort at the outset of the Company's study is designed to clear the path for using the experimental topical treatment on the face of ACD patients. Because of the high prevalence of symptoms on the face of ACD patients, the expansion of the study to facial symptoms is expected to address an important aspect of the disease, while expanding the potential patient population.

Edesa Biotech, Inc. (EDSA), closed Monday's trading session at $0.20, up 24.1465%, on 1,466 volume with 1 trade. The average volume for the last 3 months is 3,445 and the stock's 52-week low/high is $0.05/$0.531000018.

chart

First Vanadium Corp. (FVANF)

Stock Gumshoe, TalkMarkets, Stock News Now, Northern Miner, Streetwise Reports, Mining Feeds, OTC.Watch, Metals News, Junior Mining Network, Investing News, InvestorX, Resource World, OTC Markets, Geology for Investors, Barchart, Dividend Investor, PR Newswire, Investor Ideas, Stockwatch, Investors Hangout, Central Charts, Stockhouse, and InvestorsHub reported previously on First Vanadium Corp. (FVANF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

First Vanadium Corp. engages in the acquisition, exploration, evaluation, and development of mineral properties in the U.S and Canada. It explores for copper, silver, zinc, and gold minerals. The Company’s Board, Management, and Technical Team is an assembled group of experienced, respected, and successful explorers, mine builders, and mine operators.

The Company previously went by the name Cornerstone Metals, Inc. It changed its name to First Vanadium Corp. in September of 2018. OTCQX-listed and incorporated in 2006, First Vanadium has its corporate headquarters in Vancouver, British Columbia.

The Company has an option to earn a 100 percent interest in the Carlin Vanadium Project, positioned in Elko County, 6 miles south from the town of Carlin, Nevada and Highway I-80. The Carlin Vanadium Project hosts the Carlin Vanadium deposit that is flat to shallow dipping and at shallow depths with a strike length of about 1,800 meters, width averaging 600 meters, and thickness ranging from 15 meters to 50 meters. The Carlin Vanadium Property comprises 150 unpatented mining claims and 80 acres of fee simple land encompassing 2,608 acres.

The Company also has its The West Jerome Property. The focus of this Property is in the copper-rich district of Arizona, near the Town of Jerome, Central Arizona. First Vanadium owns 100 percent (subject to 1.5 percent NSR) of the West Jerome property, on the south side of Freeport McMoRan patented lands. This Property lies in a Volcanogenic Massive Sulfide (VMS) camp. The West Jerome Property is a high-grade, massive sulfide target situasted 2.4 km south of the past-producing United Verde (32 million tons grading 4.4 percent copper, 1.5 oz/t silver and 0.04 oz/t gold).

In December 2019, First Vanadium provided a regional gravity survey as support for the high-grade gold target identified by Mr. Dave Mathewson and announced November 12, 2019 on its Carlin Vanadium Project. Numerous north-central Nevada Carlin-type gold mines and deposits are associated with gravity highs. Due to this, gravity surveys (a geophysical technique) have proven to be a vital targeting tool for gold deposits in Nevada.

Mr. Mathewson is a renowned Carlin Gold Trend specialist and geological advisor to First Vanadium. He interpreted the Carlin-style high-grade gold target at depth on the Carlin Vanadium Project (see news release dated November 12, 2019) based on several factors; his familiarity with the area, structure, regional gravity data, and mineralized and altered rock exposures and intercepts from drilling along the 9 mile trend.

Mr. Paul Cowley, President & Chief Executive Officer, stated, "Collectively these supporting features made a sound story but the convincing factor for Mr. Mathewson was the coincidental gravity anomaly. While the Company remains focused on advancing its vanadium resource through the completion of the ongoing Preliminary Economic Assessment (PEA), management sees this compelling gold target as a valuable augment and is currently exploring several options to advance it, including by strategic JV partners, while advancing its vanadium resource."

First Vanadium Corp. (FVANF), closed Monday's trading session at $2.26, even for the day, on 49 volume with 1 trade. The average volume for the last 3 months is 1,780 and the stock's 52-week low/high is $0.50/$3.79999995.

chart

Friendable, Inc. (FDBL)

NetworkNewsWire, Pink Investing, TradeKing, HotStocked, Speculating Stocks, Emerging Growth, CSIMarket, Stock Market Watch, Market Exclusive, TipRanks, InvestorPoint, Investors Observer, CapitalEquity Review, OTC Markets, OTC.Watch, Stockaholics, Simply Wall St, Wallet Investor, The Hot Penny Stocks, Macroaxis, TradingView, Insider Financial, EIN Presswire, Morningstar, GuruFocus, YCharts, Investing.com, InvestorsHub, GlobeNewswire, Nasdaq, Accesswire, Stockopedia, Stockwatch, last10k, Barchart, Ceo.ca. Seeking Alpha, and Stockhouse reported earlier on Friendable, Inc. (FDBL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Friendable, Inc. is a mobile centered technology and marketing company listed on the OTC Markets. It connects and engages users via two distinctly branded applications. These are the Friendable and Fan Pass mobile applications. Fundamentally, Friendable is a mobile technology enterprise that develops, acquires, as well as invests in mobile applications with a social emphasis. The Company previously went by the name iHookup Social, Inc. It changed its name to Friendable, Inc. in September of 2015. Established in 2007, Friendable has its corporate headquarters in Campbell, California.

The Company first released its flagship product, Friendable, as a social application where users can create one-on-one or group-style meetups. Last year, it released its new version of Friendable with a concentration on dating and building subscription based revenue, beginning with its existing and historical database of roughly 900,000 registered users.

Scheduled for release this year, Fan Pass is Friendable’s newest app/brand. Fan Pass focuses on connecting Fans of their favorite celebrity or artist, to an exclusive VIP or Backstage experience. This is from their smart phone or other connected devices. Fan Pass permits an artist fan base to experience something they would otherwise never have the opportunity to afford or geographically attend. Furthermore, Friendable’s business model enables artists, musicians, and celebrities to leverage their social media followers and invite them to the show.

Last month, Friendable announced that it is approaching its next release of its “Friendable Mobile Dating App”. This includes a Web Version for those more comfortable browsing on their computer rather than a mobile device.

Mr. Robert A. Rositano, Jr., Chief Executive Officer of Friendable, said, “As Friendable and our management team continues to focus on the release of “Fan Pass,” our live streaming video app that aims to provide all Fans a backstage experience right from their smart phone, we also recognize the Friendable dating app as an important asset.”

Friendable, Inc. (FDBL), closed Monday's trading session at $1.90, up 11.7647%, on 42,079 volume with 28 trades. The average volume for the last 3 months is 29,819 and the stock's 52-week low/high is $0.414999991/$7.50.

chart

Fuling Global, Inc. (FORK)

Zacks, FairlyValued, Stock Twits, ShareInvestor.com, MacroTrends, StockInvest.us, Market Chameleon, Nasdaq, Seeking Alpha, Investing.com, Street Insider, PR Newswire, Super Stock Screener, Infront Analytics, Morningstar, MarketBeat, Simply Wall St, MarketWatch, and Dividend.com reported previously on Fuling Global, Inc. (FORK), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Fuling Global, Inc. manufactures and distributes plastic and paper serviceware for the foodservice industry. The Company has precision manufacturing facilities in the USA, Mexico and China. Fuling Global sells its products directly, and also via distributors to dealers, QSRs (Quick Service Restaurants), manufacturers, and retailers. Formed in 2015, Fuling Global is based in Wenling, the People's Republic of China (PRC). The Company’s shares trade on the NasdaqCM.

Fuling Global’s plastic and paper serviceware products include disposable cutlery, drinking straws, cups, plates, as well as other plastic and paper products. These products are used by greater than 100 customers mainly from the USA, China and Europe. These customers include Burger King, KFC (China only), McKesson, Subway, Taco Bell, Walmart, and Wendy's.

Fuling Global currently has four factories in China and one in the USA with more than 1,500 employees. The annual production capacity is about 50,000 tons including GPPS,PS,PP,PLA,PET. The Company’s largest customer base is in the United States, which accounts for greater than 90 percent of its revenues.

Last month, Fuling Global announced that Ms. Peng (Gillian) Hu was named Chief Financial Officer. Before joining Fuling Global, Ms. Hu was the Financial Controller at Hunan International Economics University, which is a subsidiary of Nasdaq-listed Laureate Education, Inc. She formerly held auditor positions at Friedman LLP and Ernst & Young.

At present, Ms. Hu serves on the Board of Directors as Audit Committee Chair at China Eco-Materials Group Co. Ltd. China Eco-Materials has filed an F-1/A registration statement with the U.S. Securities and Exchange Commission (SEC) for an Initial Public Offering (IPO).

Xinfu Hu, Chief Executive Officer of Fuling Global, said in January, "A highly experienced and skilled financial executive, Gillian has significant Chinese GAAP and US GAAP accounting experience, and we are excited that she is joining Fuling Global at an important juncture in our evolution."

Fuling Global, Inc. (FORK), closed Monday's trading session at $0.0107, up 4.902%, on 21,800 volume with 3 trades. The average volume for the last 3 months is 30,520 and the stock's 52-week low/high is $0.009999999/$0.379999995.

chart

GSRX Industries, Inc. (GSRX)

RedChip, Barchart, Stockhouse, InvestorsHub, Euro Investor, Central Charts, Wallet Investor, Trading View, OTC Markets, Last10k, 4-Traders, Teletrader, Technical420, and Simply Wall St reported previously on GSRX Industries, Inc. (GSRX), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

GSRX Industries, Inc., by way of its subsidiaries, acquires, develops, and operates retail cannabis dispensaries and non-THC CBD retail stores. In addition, the Company is in the process of expanding its business to include distribution, lite manufacturing and delivery of cannabis and cannabinoid products. GSRX Industries’ shares trade on the OTC Markets’ OTCQB. The Company has its head office in Dorado, Puerto Rico. The Company previously went by the name Green Spirit Industries, Inc. It changed its name to GSRX Industries, Inc. in July of last year.

At present, the Company operates five cannabis dispensaries in Puerto Rico under the name Green Spirit RX, and one dispensary in California under the name The Green Room. GSRX also has five additional pre-qualified locations in Puerto Rico, all of which are in different phases of development and construction. Moreover, the Company owns and operates the e-commerce site GetPureAndNatural.com, which offers a wide array of Premium Hemp Extract CBD products.

Recently, GSRX Industries announced that it purchased Units representing membership interests in Buzznog, LLC. Buzznog owns and operates Buzznog, which is a direct-to-fan social media platform for live events and activations.

Buzznog provides robust solutions for established and emerging artists, festivals, and brands. It features leading-edge technologies for live events, music releases and fan engagement. Furthermore, Buzznog creates hyper-focused targeted initiatives to deliver the right content at the right time to the right audience.

GSRX Industries also announced last week that, via its wholly-owned subsidiary, Pure and Natural, LLC, it entered into a preferred partnership and advertising agreement with Buzznog. With this agreement, Pure and Natural will become Buzznog’s premier CBD partner. Buzznog’s clients include Rolling Loud Music Festival, Breakaway Music Festival, Warner Music Group, Universal Music Group, Big Machine and Madison Square Garden Company.

GSRX Industries has announced that it signed a long-term building lease in Palm Springs for what will be its second adult-use and medicinal cannabis dispensary in the State of California. Currently, GSRX owns and operates The Green Room in Point Arena, and a number of Green Spirit RX medicinal cannabis dispensaries in Puerto Rico, with two more scheduled to open there soon.

GSRX Industries, Inc. (GSRX), closed Monday's trading session at $1.50, up 28.2051%, on 345,887 volume with 566 trades. The average volume for the last 3 months is 128,147 and the stock's 52-week low/high is $0.449999988/$3.75999999.

chart

Focus Universal, Inc. (FCUV)

Amigo Bulls, Zacks, Simply Wall St, Stockhouse, last10K, Stockopedia, CapitalCube, The Street, Awesome Penny Stocks, Whale Wisdom, Penny Stock Hub, OTC Markets, TradingView, Business Insider, Barchart, Investors Hangout, Financial Content, Street Insider, and Investing News Alerts reported earlier on Focus Universal, Inc. (FCUV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Focus Universal, Inc. is a universal smart instrumentation platform developer and universal smart device manufacturer in the IOT (Internet of Things) market. The Focus Universal technology features a Universal Smart Instrumentation Platform (USIP). The USIP provides an inventive and universal solution for embedded design, industrial control and monitoring. Focus Universal is based in Walnut, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Regarding Focus Universal’s services, the Company offers Large Scale Custom Installation. It can map out any commercial installation requirements and customize a package of devices and sensors to fit any needs.

The above-mentioned USIP uses a mobile device or computer to communicate with smart devices to monitor and control any functions. Consequently, it replaces traditional instrument hardware. The features of the Focus Universal USIP include Universal Customization; Cost Saving; Interoperability; Security; Ease of Use; Scalability; Cloud Instrumentation; and Fast Prototyping.

The smart app interface supports real-time data monitoring. It facilitates instrument control and operation. A wireless data logger (Ubiquitor) acts as a link between the smart device and sensor data acquisition module. The Universal Smart Controller (USC) permits a user to control any device by plugging the sensors into the platform using their smartphone.

Recently, Focus Universal announced that it appointed Mr. Greg Butterfield as an independent Board Member to the Focus Universal team. Mr. Butterfield is a proven entrepreneur in the technology sector and active member in the technology community. He is the Founder and Managing Partner of SageCreek Partners ('SCP') a technology commercialization and consulting firm.

Desheng Wang, Focus Universal Chief Executive Officer, said, ''Mr. Butterfield has a fantastic background in the technology sector that we believe can add great value to our board. He brings expertise in M&A and management experience with both private and public companies that will be a great addition moving forward.''

Focus Universal, Inc. (FCUV), closed Monday's trading session at $0.007, up 27.2727%, on 10,600 volume with 3 trades. The average volume for the last 3 months is 16,652 and the stock's 52-week low/high is $0.004/$0.082999996.

chart

Metrospaces, Inc. (MSPC)

Stockwolf, Investors Hangout, Street Insider, Penny Stock Tweets, Stockhouse, Stock of the Week, InvestorsHub, OTC Markets, ClayTrader, Small Cap Network, Insider Financial, Barchart, WalletInvestor, MarketWatch, Emerging Growth, and Street Register reported earlier on Metrospaces, Inc. (MSPC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Metrospaces, Inc. is a real estate investment and development Company. It acquires land, designs builds, and develops, then resells condominiums and Luxury High-End Hotels, chiefly in urban areas of Latin America. The Company is operated by a premier group of real estate and investment professionals and entrepreneurs located in New York, New York; Miami, Florida; and Buenos Aires, Argentina. Metrospaces’ current projects are in Buenos Aires, Argentina, and Caracas, Venezuela.

A start-up real estate private equity firm, Metrospaces is based in New York City. The Company’s refocusing of its business plan to U.S.-based projects is now complete. Metrospaces has strong relationships with Investment Bankers, Real Estate Entrepreneurs, Political Leaders and High Net-Worth Individuals around the world. The Company’s focus is on mid-sized deals.

Metrospaces looks to use its international relationships in financing and real estate developers to find co-investment and development opportunities in home building, residential and hotel. Furthermore, it will invest in operating companies that are real estate based. This includes hotel operators and senior facilities operators. Metrospaces will also invest in corporate reorganization.

The Company focuses on joint ventures (JV’s) with established players. Metrospaces’ majority shareholders have partnered with Investors on elite properties including The London BLVGARI 5 Star Hotel and are presently involved in negotiations for the development of a number of elite luxury properties in South America.

Metrospaces has executed a JV Agreement with Prohotels of Argentina. The agreement calls for the development of four new hotels in the coming three years.

Recently, Metrospaces announced a management decision to focus capital resources to its Cannabis-related real estate Company, CannPartners. At present, Metrospaces is looking at two properties, one in Connecticut and one in California. The Company is also keeping a strong focus on the New York market. It is in advanced talks for acquisition of those properties.

Mr. Oscar Brito, Metrospaces Executive President, said, “The continuing legalization of medical and recreational cannabis growing and distribution will continue in the US for the foreseeable future. Many investors are focusing on the grow, distribution and ancillary industries such as paraphernalia etc. However, even with the billions of dollars currently being invested in the cannabis industry, there are very few institutional investors solely focusing on the cannabis-related real estate side of the business. In our opinion, this represents a once-in-a-generation opportunity to buy distressed and real estate located in out-of-favor locations across the U.S.”

Metrospaces, Inc. (MSPC), closed Monday's trading session at $0.0377, up 21.6129%, on 38,800 volume with 9 trades. The average volume for the last 3 months is 32,486 and the stock's 52-week low/high is $0.027899999/$0.194999992.

chart

AEON Global Health Corp. (AGHC)

Amigo Bulls, Stock Target Advisor, Stockopedia, Investors Hangout, Penny Stock Hub, Stockwatch, Simply Wall St, Zacks, Stockhouse, InvestorsHub, YCharts, TradingView, The Street, Stockflare, and Dividend Investor reported on AEON Global Health Corp. (AGHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AEON Global Health Corp., together with its subsidiaries, provides a variety of clinical laboratory testing services in the United States. The Company provides diagnostic services in Cancer Genomics, Toxicology, Pharmacogenomics, as well as Health Technology Applications. AEON formerly went by the name Authentidate Holding Corp. It changed its name to AEON Global Health Corp. in January 2018. OTCQB-listed, AEON Global Health has its corporate office in Gainesville, Georgia.

The Company is the fastest growing clinical lab and healthcare services organization in the United States. It is first in healthcare technology research and development (R&D) where its proprietary methodologies provide expedited and highly accurate urine and oral fluid (saliva) test results. AEON’s chief business focus is providing a “personalized medicine” approach to laboratory testing services. This is to provide customers with actionable medical information.

AEON is an innovator in the genomic testing area. The Company has an extensive menu of genetic tests and a pipeline of additional molecular-based tests in development. It provides post contract customer support services. The design of AEON’s Telehealth Solutions is to improve outcomes and reduce hospital readmission through helping clinicians closely monitor patients with chronic illnesses. These include CHF, COPD and Diabetes.

Concerning Toxicology Testing, AEON Global Health provides accurate and fast quantitative testing of drug metabolite levels in urine and oral fluids. The Company’s testing covers more than 80 analytes and metabolites. Its HPLC-tandem mass spectrometry can analyze wider molecular weight and polarity ranges of analytes, providing better selectivity and sensitivity.

AEON Clinical Labs services include Cancer Genomics, Pharmacogenomics, Toxicology, and Women’s Health. Health Technologies services include Inscrybe®. This is a secure and simple interface. Inscrybe® enables physicians, nurses, hospital staff, and external care facilities or health insurers to send, receive, sign, and track healthcare records, supporting documents, patient discharge orders and referrals or lab results and images on the web or via electronic fax instead of transferring paper.

In May 2018, AEON Global Health announced it earned The Joint Commission’s Gold Seal of Approval® for Laboratory Services Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal of Approval is a symbol of quality, which reflects an organization’s commitment to providing safe and effective patient care.

AEON Global Health underwent a thorough onsite survey earlier in 2018. During the review, a Joint Commission expert surveyor evaluated compliance with laboratory standards related to a number of areas. This included document and process control, healthcare-associated conditions, risk reduction, as well as staff qualifications and competency. Additionally, the surveyor conducted onsite observations and interviews.

AEON Global Health Corp. (AGHC), closed Monday's trading session at $0.47, up 27.027%, on 73,410 volume with 34 trades. The average volume for the last 3 months is 12,009 and the stock's 52-week low/high is $0.090000003/$0.469999998.

chart

Sayona Mining Limited (DMNXF)

OilandGas 360, The Street, Barchart, Your Drilling News, CentralCharts, OTC Markets, Penny Stock Hub, WalletInvestor, HotCopper, Metals News, Investors Hangout, Penny Stock Tweets, 4-Traders, Stockwatch, MarketWatch, Stockhouse, Capital Equity Review, InvestorsHub, and Predict Wall Street reported on Sayona Mining Limited (DMNXF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Sayona Mining Limited, together with its subsidiaries, engages in the identification, acquisition, evaluation, and exploration of mineral assets in Australia and globally. The Company chiefly explores for lithium and graphite. It formerly went by the name DiamonEx Limited. It changed its corporate name to Sayona Mining Limited in May 2013. Listed on the OTC Markets, Sayona Mining is based in Paddington, Australia.

Sayona Mining’s focus is on sourcing and developing the raw materials required to make lithium-ion batteries. The Company’s primary emphasis is the development of the advanced stage Authier Lithium Project in Quebec. The Authier Project is 45 kilometers northwest of the city of Val d’Or, a major mining service center in Quebec. Authier mineralization is hosted in a spodumene-bearing pegmatite intrusion with more than 18,000 meters of drilling in 139 holes.

The Authier Lithium Project has advanced, near term development potential. It has a Pre-Feasibility Study (PFS) demonstrating technical and economic viability. The Project area comprises 19 mineral claims totaling 653 hectares. It extends 3.4 kilometers in an east-west, and 3.1 kilometers in a north-south direction, respectively. The location of the Mineral claims is over Crown Land. Sayona Mining completed greater than 8,000 meters of drilling during 2016 and 2017.

The Authier Lithium Project is amenable to simple open-cut mining and processing methods. The project is in close proximity to development infrastructure. In July 2016, Sayona acquired 100 percent of the Authier project for CAD$4 million. In addition, the Company controls a portfolio of lithium and graphite exploration projects in Western Australia.

Concerning Western Australia, Sayona Mining has 17 tenements in the Pilbara Region, covering a total area of 1918km2. Of these, nine were acquired by way of a deal with Great Sandy, with the Mallina Project – E47/2983, being the flagship project.

The East Kimberley Graphite Project is Sayona’s strategic entry into the graphite market. In 2015, the Company announced a strategic entry into the large flake graphite market through securing a large ground position in the East Kimberley area of Western Australia. The Kimberley region is a proven province for high purity, large flake graphite.

The East Kimberley project is 240 kilometers south of Wyndham Port and 220 kilometers south-south-west of the regional center, Kununurra. The Project includes one granted tenement and three separate tenement applications. The Project covers 278 km2. It comprises two areas, Keller and Corkwood. Sayona Mining has 100 percent of the graphite interests across four tenements in the East Kimberley, following the completion of two option-to-purchase agreements.

Recently, Sayona Mining reported the start of a testing program to produce lithium carbonate and lithium hydroxide from the Authier pilot plant lithium concentrate. The Company recently completed a pilot plant program that processed five tons of Authier drill core into greater than 400 kilograms of spodumene concentrate.

This program demonstrated that a 6 percent Li2O concentrate could be produced at a metallurgical recovery of 79 percent. SGS Canada, Inc. will perform the downstream testing program.

Sayona Mining Limited (DMNXF), closed Monday's trading session at $0.0209, up 53.6765%, on 328,660 volume with 26 trades. The average volume for the last 3 months is 107,657 and the stock's 52-week low/high is $0.0037/$0.034000001.

chart

Inspyr Therapeutics, Inc. (NSPX)

BUYINS.NET and Zacks reported earlier on Inspyr Therapeutics, Inc. (NSPX), and today we report on the Company, here at the QualityStocks Daily Newsletter.  

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company based in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients’ with numerous different tumor types. Inspyr Therapeutics’ team has considerable pharmaceutical industry and scientific experience.

The Company lists on the OTC Markets Group’s OTCQB. It previously went by the name GenSpera, Inc. It changed its name to Inspyr Therapeutics, Inc. in August of 2016.  

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.  

Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). In addition, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.  

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program centers on the treatment of gastric cancer.

Inspyr has started a preclinical study in gastric cancer PDX tumor models that express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.   

Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. This unique platform technology has the potential to work across a range of drugs that precisely target different cancers.       

In October of 2017, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

Inspyr Therapeutics, Inc. (NSPX), closed Monday's trading session at $0.0305, up 23.7825%, on 3,430,912 volume with 200 trades. The average volume for the last 3 months is 950,494 and the stock's 52-week low/high is $0.0023/$0.035.

chart

PeerLogix, Inc. (LOGX)

MarketWatch, InvestorsHub, Stockopedia, Marketwired, OTC Markets, Stockhouse, Barchart, The Street, DreamTeamNetwork, Business Insider, and Simply Wall St. reported on PeerLogix, Inc. (LOGX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PeerLogix, Inc. is an advertising technology and data aggregation company listed on the OTC Markets’ OTCQB. PeerLogix provides a proprietary Software-as-a-Service (SAAS) platform that enables the tracking and cataloguing of over-the-top viewership and listenership. This is to determine consumer trends and preferences based upon media consumption. PeerLogix has its head office in New York, New York.

The Company’s focus is on delivering simple and flexible solutions its customers require to accurately recognize more consumers, define key audience segments, and manage customer acquisition and retention efforts. PeerLogix’s patent pending platform collects over-the-top data, including IP addresses of the streaming and downloading parties, the name, media type, and genre of media watched, listened or downloaded.

This platform uses licensed and publicly available demographic and other databases to further filter the collected data. This is to provide insights into consumer preferences to digital advertising firms, product and media companies, as well as entertainment studios and others.

The PeerLogix Real-Time Interaction System makes it easy for its clients to reach their customers who interact with their brand on numerous different channels at any time. Subsequently, the client can respond to their customers with contextually relevant messages that meet real-world needs.

PeerLogix previously announced a partnership with adsquare, the mobile-first data exchange, to provide PeerLogix data on adsquare's Audience Management Platform. The partnership will permit buyers in adsquare's Platform to buy PeerLogix's OTT engagement data comprising greater than 170 million households watching television programming, movies, or listening to music, globally.

Adsquare is the mobile-first data exchange. It brings together advertisers and data providers in a fair, secure and privacy-friendly manner. The platform has been built mobile-first and operates in real-time. It allows advertisers to take advantage of data for audience targeting and precise moment marketing.

Recently, PeerLogix announced select weekly estimates for the week ending December 10, 2017, as compiled by its proprietary measurement services. Annapurna’s “Detroit” was in first with a leading 329,000 hours streamed across all major and mid-major markets. Lionsgate Film’s Leatherface was in second with 290,000 hours streamed. Smith Global Media’s “Valley of Bones,” CJ Entertainment’s “Confidential Assignment” and Lionsgate Film’s “American Assassin,” rounded out the top five with 258, 195 and 172 thousand hours streamed, respectively.

PeerLogix is the established standard for tracking non-subscription based over-the-top viewership data of television, movies, and listeners of music worldwide.

PeerLogix, Inc. (LOGX), closed Monday's trading session at $0.048, up 31.5068%, on 32,591 volume with 5 trades. The average volume for the last 3 months is 9,957 and the stock's 52-week low/high is $0.029999999/$0.079800002.

chart

The QualityStocks Company Corner

Jerrick Media Holdings, Inc. (OTC: JMDA)

The QualityStocks Daily Newsletter would like to spotlight Jerrick Media Holdings, Inc. (OTC: JMDA).

Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, recently published a weekly update from the company’s CEO Jeremy Frommer. Among other highlights, Frommer discussed the company’s continued pursuit to expand its talented team. “We are always looking to expand our talented team. To view the full update, visit http://nnw.fm/Yprp1

Jerrick Media Holdings, Inc. (OTC: JMDA) develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience.

Jerrick’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity.

Vocal

Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy.

Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.

All content available on Vocal is created within the platform’s custom editor and published on one of Vocal’s embedded genre-specific communities, spanning topics that range from food to wellness, beauty, technology and more.

In May 2019, Jerrick launched Vocal+, its premium subscription membership program. Vocal+ members pay a membership fee for premium value-added features, including receiving increased earnings for their content, reduced platform processing fees for tips received, a Vocal+ badge on their creator page, access to new features on the Vocal Platform, and other rewards. Creators can sign up for free or upgrade to Vocal+, available for purchase on either an annual or monthly subscription basis.

 

Vocal for Brands

Vocal for Brands is an in-house creative studio that generates actionable data from bespoke native advertising campaigns. Vocal for Brands partners with direct-to-consumer (DTC) to create beautiful, campaign-optimized stories on Vocal that build brand affinity, trust and drive results.

Additionally, Jerrick provides a Managed Services offering to business-to-business (B2B) and business-to-consumer (B2C) product and service brands which encompasses a full range of digital marketing and e-commerce solutions. Managed Services includes the setup and ongoing maintenance of clients’ websites, Amazon and Shopify storefronts and listings, social media pages, search engine marketing, and other various tools and sales channels utilized by e-commerce sellers for sales and growth optimization. In addition to partnering with Managed Services clients, the company offers a range of la carte services.

Growth Strategy

Upon the consummation of its anticipated listing on the Nasdaq Capital Market, Jerrick intends to change its official company name to “Creatd, Inc.,” subject to stockholder approval.

This rebranding will initiate Jerrick’s go-forward growth strategy and its plans to expand its offerings and provide technology products and resources for creators to help transform their ideas into reality. The strategic plan is designed to greatly increase Jerrick’s potential market value via a plethora of new revenue streams.

Creatd will focus on a community of creators that number more than 2.5 billion users, for which it will offer democratized, transparent platforms for distribution, sentiment, resources and monetization. The company’s agile development process will rely on a combination of bleeding-edge technology that eliminates barriers and creates efficiencies. Superior design thinking and data analysis will allow Creatd to expand its digital footprint to a global community.

Creatd will partner with a community of technology collaborators and sophisticated investors who collaborate to provide technology solutions for creators, brands and their respective audiences. The company’s solutions, business processes, technology platforms and design theories will lend themselves to application opportunities on a global scale.

History & Management

Jerrick was founded in 2012. Initially a private media company providing online content through a portfolio of brands, Jerrick’s needs quickly outpaced its initial technology and product offering. In 2015, Jerrick partnered with Thinkmill, a premiere, Australia-based product design and development group to create a content management system (CMS) for its brands; that system evolved into the company’s flagship product, Vocal.

Today, Jerrick’s management team is an impressive group of abstract thinkers united by their passion to solve problems. Leading the team are founder and CEO Jeremy Frommer, and Justin Maury, Jerrick’s president and head of product.

Frommer’s career includes two decades in the financial technology industry, working as a hedge fund and portfolio manager, as well as on the sell-side of the financial industry. Frommer started NextGen Trading, a software development company building proprietary equity trading platforms. NextGen was acquired by Carlin Financial Group of which Frommer became CEO. RBC Capital Markets Corporation eventually bought Carlin. At RBC, Frommer was managing director, head of the Global Prime Services group and a member of the RBC Global Equities Operating Committee.

Maury joined Jerrick in 2013, bringing with him 10 years of experience in the creative industry. Since partnering with Frommer to establish Jerrick, Maury led the company’s product development for more than four years. His passion for the creative arts and technology ultimately yielded the vision for Vocal. During the Jerrick’s early formative years, Maury was a driving force in creating the vision, design and architecture for the Vocal platform and managing the oversight of technology development.

Jerrick Media Holdings, Inc. (JMDA), closed Wednesday's trading session at $1.2801, up 2.408%, on 25,343 volume with 50 trades. The average volume for the last 3 months is 49,168 and the stock's 52-week low/high is $1.08749997/$6.00810003.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

With the best-selling cannabis product in California among its powerful product lineup, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) is looking to build on its legacy of success as it plans to grow its product portfolio this year. Bolstered by the success garnered in 2019, PLUS plans on releasing two new cannabis product offerings in Q1 2020. Also today, the company was highlighted in a publication from CBDWire, examining how the CBD craze has swept over many markets. From Europe to the U.S., more and more people have been turning to cannabidiol to help manage their ailments. The chemical is extracted from the hemp plant and is said to be effective against a range of ailments from anxiety and high blood pressure to insomnia and chronic pain.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $0.22, up 15.79%, on 13,350 volume with 5 trades. The average volume for the last 3 months is 12,195 and the stock's 52-week low/high is $0.125/$0.59.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings (OTCQB: NGTF), the award-winning ice cream company addressing America’s $50 billion-dollar nighttime snacking problem, today announced its entry into an agreement with News America Marketing for Nightfood’s first-ever in-store promotional activities in several Nightfood supermarket chains. News America Marketing provides comprehensive in-store marketing media options in over 60,000 stores throughout the U.S. and Canada. To view the full press release, visit http://nnw.fm/rhgS9

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving late-night snacking for consumers and solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in the ice cream category in a Kantar survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try.

Nightfood has secured distribution in several major regional supermarket chains and has landed media coverage in major outlets such as The Today Show, The Wall Street Journal, Oprah Magazine, USA Today, The Washington Post, Parents Magazine, and many more.

Over 80% of consumers snack regularly at night, and the most popular choices are cookies, chips, candy, and, of course, ice cream. These are understood to be both unhealthy and sleep-disruptive.

Research indicates that human biological programming combined with the trappings of modern life combine to drive this unhealthy behavior pattern. Every week, hundreds of millions of Americans combine to spend an estimated $1B on snacks consumed between dinner and bed.

In a recent Harris Poll online study, 54% of consumers who snack at night reported often feeling guilty about their nighttime snack choices. 58% said they wish they felt more in control of their nighttime snacking.

Nightfood management believes that the company that solves this massive consumer problem can become a national brand with a billion-dollar valuation.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc. was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company is seeking licensing opportunities to market such products under the brand name “Half-Baked,” for which they’ve successfully secured trademark rights.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former vice president of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Christensen led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small-cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.01463, up 5.25%, on 11,099,794 volume with 244 trades. The average volume for the last 3 months is 10,992,233 and the stock's 52-week low/high is $0.0123/$0.16.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (CIIX) was featured today in the 420 with CNW by CannabisNewsWire. One major part of the travel industry is the hotel, and with the legalization of marijuana taking place in more and more states in the U.S., hotels are facing several challenges concerning marijuana consumption. They are faced with the issue of figuring out how to allow their guests to partake in marijuana consumption within their properties, training and drug testing their staff, and how to deal with the changing marijuana laws.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.0011, off by 8.33%, on 18,485,335 volume with 60 trades. The average volume for the last 3 months is 5,012,335 and the stock's 52-week low/high is $0.0005/$0.0085.

Recent News

chart

No Borders Inc. (OTC: NBDR)

The QualityStocks Daily Newsletter would like to spotlight No Borders Inc. (NBDR).

No Borders Inc. (OTC: NBDR) came to the fore during the 2018 blockchain boom, and has since grown and developed by relying on an anti-fragile approach of deploy, test, adjust and repeat, by which it intends to stand throughout 2020, according to a Random Analyst assessment of the company’s road map for next year (http://ccw.fm/U88za).

No Borders Inc. (OTCQB: NBDR) specializes in the acquisition, creation and scaling of commercial products by utilizing cutting-edge technologies designed to reduce costs while increasing revenues and shareholder value. With active subsidiaries in healthcare, education, cannabidiol (CBD), finance and technology, No Borders is uniquely positioned to use its expertise to improve margins and add business lines within target verticals. No Borders is headquartered in Arizona with remote work resources in the U.S., South America, Asia and Europe.

Different by Design

Deeply experienced at actionable data compilation, analysis and utilization, No Borders believes that data utilization in a Web 3 ecosystem of predictive analytics, blockchains, consensus algorithms, IoT and 5G are vital keys to the future of disrupting global business.

The company leverages its technological talent and visionary approach alongside best-in-class branding, messaging and product teams to simultaneously deploy multiple vertical product offerings at the same time.

With resources around the world, No Borders operates as a 100% remote work, lean operating organization with a founding ideological focus on “Lifestyle by Design.” No Borders’ teams are built by allowing people to work when they want and from where they want as long as deliverables and results are achieved. This structure allows for strategic talent acquisition without the need for relocation or commuting; lowered operating and fixed costs; as well as improved morale and substantially increased staff productivity.

NBDR Companies

  • No Borders Dental Resources Inc. provides equipment and supplies to medical and dental professionals across the U.S. through the trade name, MediDent Supplies. MediDent has a strategic focus on expanding product portfolios and optimizing lifetime customer value while minimizing customer acquisition cost in the medical, dental and veterinary spaces.
  • No Borders Naturals is a purveyor of health and wellness products for active consumers and their pets. No Borders Naturals aims to be an industry leader in alternative wellness product offerings and is currently expanding its digital offering with impactful product up-sell opportunities such as a series of “Buy Two-Get One” on products on its 1000mg CBD tincture, collagen and retinol beauty cream.
  • No Borders Labs Inc. provides leading-edge tech tools to the No Borders family of companies along with building, testing and deploying technology solutions and products to the market while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency.
  • No Borders Funding Inc. provides internal capital and strategic funding options for the family of No Borders companies while actively engaging and networking to find, acquire, structure and deploy unique financial products, solutions and systems with traditional, distributed ledger and blockchain technologies.
  • No Borders Education Inc. provides internal staff training and strategic education tools for the No Borders family of companies while pursuing external revenue generating educational opportunities within the verticals for which No Borders deploys products, services or technologies.

 

Leadership

No Borders CEO Joseph Snyder is a serial entrepreneur whose experiences in real estate investment, financial services and digital strategy over the last 15 years provide a strong, grounded foundation for the structure and ideas outlined in the company’s strategic plan. He brings a unique set of long-term business experiences that provide No Borders with a clear “mile-high” view of the intricately linked systems and challenges associated with growing and scaling our vision.

COO Cynthia Tanabe, a licensed real estate agent/broker since 2004, has successfully built a highly respected investor and bank-focused real estate and property management firm in Arizona with tens of millions of dollars of properties owned and sold.

CTO Chris Brown has 14 years of experience in the IT industry ranging from full stack programming, hardware support, engineering and maintenance, to enterprise-level information system analysis, design, development and implementation. From his background in Air Force intelligence to earning dual B.S. degrees in computational mathematics and biochemistry from Arizona State University, Brown has been engrossed with technologies such as artificial intelligence, machine learning, and decentralized blockchain ledger systems and their connections with real world business applications.

Management is backed by an advisory board with a diverse range of expertise blockchain, brand development, specialty retail, branded consumer products, technology, marketing and other specialties pertinent to No Borders’ growth strategy.

No Borders Inc. (NBDR), closed the day's trading session at $0.01463, up 5.25%, on 11,099,794 volume with 244 trades. The average volume for the last 3 months is 10,992,233 and the stock's 52-week low/high is $0.0123/$0.16.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX)today announced the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. To listen to the interview, visit http://nnw.fm/rn9rA To view the full press release, visit http://nnw.fm/oKn0M.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $0.088, even for the day. The average volume for the last 3 months is 34 and the stock's 52-week low/high is $0.072159998/$0.208299994.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) was featured today in a publication from HempWireNews, examining how in October 2019, the U.S. Department of Agriculture (USDA) released the much-awaited interim final rule on hemp, finally giving the budding hemp industry a comprehensive regulatory structure. However, as hemp producers went through the interim final rule, they realized that it wasn’t the Hail Mary many thought it would be. In the following months, there have been numerous complaints that the federal rules are too tough, and they might spell doom for the sector.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.9849, up 1.02%, on 82,917 volume with 83 trades. The average volume for the last 3 months is 117,159 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was highlighted today in a publication from Stock Markets Press, examining how CBD branding represents an opportunity in the emerging category for large and small suppliers. This is a marketplace where consumers want to try CBD product, but still have not developed loyalty to any one brand.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.0369, up 3.51%, on 163,712 volume with 431 trades. The average volume for the last 3 months is 243,914 and the stock's 52-week low/high is $2.784/$7.565.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) was highlighted today in a publication from Stock Markets Press, examining how CBD is now mainstream, available in multiple store locations even in upscale and conventional brick-and-mortar malls.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees and culture of innovation. The company aims to grow the world’s best legal cannabis and become a leader in the global industry. Supreme Cannabis calls its Toronto Venture Exchange stock symbol, “FIRE,” a testament to the company’s passion for cannabis and obsession with quality.

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as one of Canada’s most premium cannabis producers, the company sees itself at the center of this global shift.

A key piece of Supreme Cannabis’ ability to fulfill its mission is its flagship brand, 7ACRES, a wholly owned subsidiary that operates a 440,000-square-foot hybrid cultivation facility in Kincardine, Ontario. 7ACRES is focused on building a core competency in scaled high-quality cannabis production. With a best-in-class cultivation facility producing a competitive product that fuels a leading premium brand, Supreme Cannabis has achieved a differentiated advantage in cultivation IP, products and branding. The company’s foundational investment in premium cultivation has secured it a leadership position in the industry as the Canadian market becomes more competitive and matures.

Since legalization, 7ACRES has brought five premium flower strains to market in Canada. The demand for 7ACRES product continues with the company’s most recent launch of Jack Haze, a new proprietary premium cultivar. The company’s first sativa-dominant strain, Jack Haze offers rare sensory characteristics, delivering high THC content with a terpinolene forward profile, including a complex aroma with notes of citrus, pine and warm spice. As it develops its next winning strain, 7ACRES continues to prioritize subjective quality. In the Canadian cannabis market, this approach has established 7ACRES as a well-known premium brand that commands premium pricing coast-to-coast.

In addition to 7ACRES, Supreme Cannabis has built a diversified portfolio of focused consumer-driven brands:

  • Sugarleaf by 7AC – this new brand widens Supreme Cannabis’ product offerings and targets consumers who are looking for more refined, milder consumption experience as they discover their own cannabis taste preferences and desires. Product formats under this brand are focused on offering consumers elegant and convenient cannabis experiences.
  • Blissco — dedicated to providing wellness focused consumers with premium cannabis products, education, and outstanding customer care. Blissco is focused on bringing its collection of premium whole-flower CBD oils to market.
  • Truverra — focused on being a global leader in the development, production and marketing of hemp and cannabis-derived medicinal products with clinically proven efficacy. With over 25 SKUs sold online in the UK and Europe, Truverra is ideally positioned to address emerging international cannabis opportunities.
  • Khalifa Kush Enterprises — formed through a prestigious international partnership with Khalifa Kush Enterprises (KKE) Canada, the Canadian counterpart to the popular U.S. cannabis brand KKE formed by Wiz Khalifa. Together, Supreme Cannabis and KKE Canada are developing and launching a lineup of premium cannabis products, including a future line based on the well-known Khalifa Kush strain.

Each of Supreme Cannabs’ brands and partnerships have been strategically identified and designed to support the company’s mission to enhance the lives of consumers through positive cannabis experiences. Equally important to delivering desirable consumer experiences is the infrastructure supporting the company’s brands and products. From seed to sale, supreme cannabis continues to build an impressive group of operating assets that serve key functions throughout the value chain:

  • Cultivation – for starters, there is Supreme Cannabis’ foundational flagship asset, its 440,000-square-foot cultivation facility in Kincardine, Ontario. With over 600 employees, 24 grow rooms, and best-in-class processing equipment and procedures, this facility is expected to reach an annual production capacity of 50,000 kilograms in the near-term. In this purpose-built facility, the company grows small-batch high-quality cannabis from 10,000-square-foot grow rooms and completes a proprietary hang-dry for up to two weeks.
  • Extraction – with the acquisition of Blissco in fiscal 2019, in addition to the Blissco wellness brand, Supreme Cannabis gained a 12,000-square-foot dedicated extraction facility in Langley, BC. This facility conducts both C02 and ethanol extraction and with the recent receipt of its oil sales license from Health Canada, it now produces Blissco branded CBD oils and expects to fill vaporizer pods for a partnership between the company’s 7ACRES brand and Pax Labs.
  • Manufacturing – most recently, the company announced its 107,000-square-foot processing, packaging and manufacturing facility in Kitchener, naming the facility Supreme Cannabis Kitchener. In Q4 FY2020, the company expects to begin whole flower packaging and pre-roll manufacturing for Supreme Cannabis brands at the Kitchener Facility. In the long-term, in additional to processing its own inputs, Supreme Cannabis intends generate incremental revenue by packaging, distributing and branding third-party cannabis inputs from quality-focused cultivators.
  • R&D and Product Testing – In Q1 FY2020, Supreme Cannabis closed the acquisition of Truverra and acquired a 5,000-square-foot facility licensed under Canadian Clinical Cannabinoids Inc. in Scarborough, Ontario (“Supreme Cannabis Scarborough”). Supreme Cannabis Scarborough provides R&D space for the company to test new products and develop medicinal science intellectual property. In the near-term, with the legalization of 2.0 cannabis products, this centre for innovation will be testing and bringing concentrate products to market under the 7ACRES brand.

Supreme is committed to continue to identify new opportunities to grow and strengthen its impressive portfolio of operating assets and brands and scale its strong Canadian business globally.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $3.60, up 34.83%, on 3,388,904 volume with 4,979 trades. The average volume for the last 3 months is 1,322,318 and the stock's 52-week low/high is $1.87/$7.89.

Recent News

chart

Neutra Corp. (OTCQB: NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR).

Neutra Corp. (OTC PINK:NTRR) announces that it has received a new round of private equity on the 1st of January 2020 that the company intends to use in its ongoing campaign to become a vertically integrated producer, manufacturer and distributor of hemp-based CBD health products.

Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.

Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.

Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.

Acquisitions

  • VIVIS – Neutra continues to expand its market presence in the rapidly growing hemp-derived CBD market and recently acquired VIVIS, an emerging retail brand of hemp-based health and nutritional products. VIVIS’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With VIVIS as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
  • J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.

Partners

  • Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
  • ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.

Leadership

Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.

Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.

Neutra Corp. (OTCQB: NTRR), closed Tuesday's trading session at $5.57, up 1.8282%, on 914,374 volume with 3,140 trades. The average volume for the last 3 months is 1,062,282 and the stock's 52-week low/high is $2.97000002/$8.43999958.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics (OTCQB: ENDV) today announced the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. To view the full press release, visit http://nnw.fm/VnHV4

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Steven C. Levin, M.D., Scientific Advisory Board Member
Dr. Steven C. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology. Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. Additionally, Dr. Levin has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center. Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.

Peter Novak, M.D., Ph.D., Scientific Advisory Board Member
Dr. Peter Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

Geoffrey Abrams, M.D., Scientific Advisory Board Member
Dr. Geoffrey Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for Stanford’s varsity athletes. He specializes in orthopedic sports medicine and arthroscopy of the shoulder, knee and elbow as well as upper extremity joint replacement surgery. Dr. Abrams is a member of the American Academy of Orthopedic Surgeons (AAOS) and the American Orthopedic Society for Sports Medicine (AOSSM), among others, and currently serves as assistant team physician for the NFL’s San Francisco 49ers as well as head team physician for a number of Stanford University varsity athletic teams. He is actively involved in research focusing on the role of inflammatory mediators, and microRNA in particular, on cartilage and tendon damage. Dr. Abrams received his undergraduate degree from Stanford University and his doctorate of medicine from the University of California – San Diego. He completed his residency in orthopedic surgery at Stanford University and went on to receive additional training in Orthopedic Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Abrams has authored or co-authored over 60 peer-reviewed scientific articles, over 20 book chapters, has presented original research at numerous national and international scientific meetings, and serves as a reviewer for numerous sports medicine scientific journals.

Dr. William Li, Scientific Advisory Board Member
Dr. William Li is CEO and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies. Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost-effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.

Mykol Larvie, Scientific Advisory Board Member
Recipient of three Harvard Medical Student Teaching awards in Principal Clinic Experience, Mykol Larvie is currently a radiologist in the Cleveland Clinic’s Divisions of Nuclear Medicine and Neuroradiology as well as the director of Functional and Molecular Neuroimaging. With a completed internship in the Department of Medicine as well residency in the Department of Radiology and fellowship in the Division of Neuroradiology at the Massachusetts General Hospital, Dr. Larvie specializes in PET examinations of the brain performed typically for the evaluation of neurodegenerative disease, seizure and tumor. He delivers didactic lectures and case conferences to residents and fellows six times per year and serves as a mentor and advisor to medical students, residents and fellows.

Nathan L. Guerette, Scientific Advisory Board Member
Nathan L. Guerette is the director and president of the Female Pelvic Medicine Institute of Virginia; an associate clinical professor in the division of Urogynecology and Pelvic Reconstructive Surgery at the Medical College of Virginia; a full clinical professor in Urogynecology and Pelvic Reconstructive Surgery at the Riverside Regional Medical Center; and the Robotic Surgery director at the Chippenham and Johnston Willis Medical Center. With a completed fellowship in urogynecology and pelvic reconstructive surgery at the Cleveland Clinic Foundation, Dr. Guerette has won seven awards in the medical and humanitarian departments. He has made nine media appearances, some of which were on PBS and NBC News. He has three board certifications and has ran a surgical mission trip to Trujillo, Peru, through Bon Secours.

Dr. Ashling O’Connor, Scientific Advisory Board Member
Currently a surgeon at the Comprehensive Breast Health Center of the Lahey Medical Center, Dr. O’Connor has won seven awards in the surgical department. She has completed a surgical internship at the Mater Misericordiae Hospital in Dublin as well as a breast surgery fellowship at the University of Massachusetts Interdisciplinary Breast Fellowship. She mentors medical students and surgical residents both in the operating room and in a clinical setting and enjoys biking and triathlons as well as trail and marathon running. She is certified in the Hidden Scar technique in breast surgery as well as in the advanced cardiac life support and is a member of the Protocol Review Committee Umass Memorial Medical Center, the New England Surgical Society and the American College of Surgeons.

Samir Awad, Scientific Advisory Board Member
Samir Awad has worked for the Department of Veterans Affairs since 2000. He has served as the operative care line associate executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad’s areas of specialty include liver, pancreas, and acute care surgery, as well as minimally invasive surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine. Dr. Awad has authored more than 100 peer-reviewed and invited publications and is the recipient of numerous awards for surgical and research achievements. Dr. Awad is certified by the American Board of Surgery and Surgical Critical Care.

Endonovo Therapeutics Inc. (ENDV), closed the day's trading session at $3.531, off by 1.09%, on 97,568 volume with 166 trades. The average volume for the last 3 months is 76,455 and the stock's 52-week low/high is $2.81/$6.008.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.032, off by 5.88%, on 4,136,196 volume with 260 trades. The average volume for the last 3 months is 7,656,739 and the stock's 52-week low/high is $0.0132/$0.415.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $0.293, off by 0.03%, on 23,081 volume with 23 trades. The average volume for the last 3 months is 23,504 and the stock's 52-week low/high is $0.01/$0.80.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF).

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (OTCQB: HTPRF), closed Friday's trading session at $6.03, up 0.332779%, on 14,139 volume with 117 trades. The average volume for the last 3 months is 33,423 and the stock's 52-week low/high is $5.05999994/$11.50.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.